Rosemont Pharmaceuticals agrees to acquire Aytu BioPharma for $2.70 per share
AYTU•Rosemont Pharmaceuticals agreed to acquire Aytu BioPharma for $2.70 per share in cash through a tender offer followed by a merger. The offer represents premiums of 41.1% to Aytu’s 30-day volume-weighted average price and 51.7% to its November 13, 2026, closing price.




